Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

STEMI: early-phase trial registry

2 of 5 indexed STEMI trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

STEMI: 5 US clinical trials tracked, 2 recruiting.

STEMI is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Stealth BioTherapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition stemi

OPEN 2 | RECR 40% | LATE 0 | EARLY 2 | RANK #3391 | SPON 1

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%STEMI (this)40%
Open-enrollment share among volume-matched conditions near STEMI

STEMI lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for STEMI on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. STEMI is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates STEMI research.

    Stealth BioTherapeutics accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical STEMI enrolment sits around 300 participants.

    Median target enrolment is 300 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. STEMI research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on STEMI records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bendavia (MTP-131) Drug
1 trials
TEE probe Device
1 trials
Placebo, 150 mL intravenously, once Other
1 trials
Atibuclimab (IC14), 20 mg/kg intravenously, once Drug
1 trials
PCI Device
1 trials
TherOx DownStream System Device
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on STEMI trials. A trial with sites in several states counts in each.

Virginia 1 trials
Pennsylvania 1 trials
Nebraska 1 trials
Missouri 1 trials
Michigan 1 trials
Massachusetts 1 trials
Indiana 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this STEMI page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This STEMI condition card totals 5 registered trials; most-linked intervention Bendavia (MTP-131); top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.